This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Sarilumab - Indications, Dosage, Side Effects and Precautions — Description, Dosage, Side Effects | PillsCard
OTC
Sarilumab - Indications, Dosage, Side Effects and Precautions
150 mg/1.14mL, Injection, solution
INN: SARILUMAB
Available in:
🇬🇧🇵🇹
Form
INJECTION, SOLUTION
Dosage
150 mg/1.14mL
Route
SUBCUTANEOUS
Storage
—
About This Product
Manufacturer
Sanofi-Aventis U.S. LLC
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
ATC Code
L04AC14
Source
OPENFDA_NDC
Sarilumab is prescribed for the treatment of moderate-to-severe rheumatoid arthritis in adult patients who have not shown adequate response either to one or more disease-modifying antirheumatic drugs (DMARDs).
Rheumatoid arthritis is an autoimmune disease in which the body’s immune system mistakenly attacks its own joints resulting in pain, swelling, and inflammation.
Sarilumab is used alone or in combination with
methotrexate
or other DMARDs.
It works by blocking the activity of interleukin-6, a cytokine substance that is responsible for causing inflammation.
⚠️ Warnings
• Sarilumab may increase the risk of infection by lowering the immunity. Therefore, patients with any symptoms of infection should report to the doctor instantly for further evaluation and treatment.
• Patients are required to test for latent tuberculosis (where patient is infected with Mycobacterium tuberculosis but does not have active tuberculosis). If found positive, tuberculosis treatment should be initiated before sarilumab. Patients should be monitored closely for tuberculosis infection during treatment even if they were negative for latent tuberculosis.
• If the patient shows any sign or develops a serious infection, the treatment with sarilumab must be stopped until the infection comes under control.
• Incidence of infection rate is higher in the elderly population and caution is required in treating these groups.
PillsCard reference image